Thanks to the funding, Enzybiotx has carried out the following activities:
a) An extensive market, regulatory and growth strategy was ordered from a consultancy company experienced in biotech and med-tech markets. The company has also carried out a very detailed comparative analysis of various licensing agreements from all over the world to determine best strategy for Enzybiotx in terms on fees (upfront and royalty) as well as additional terms and conditions of such agreements. The analysis covered two markets, which Enzybiotx has identified as the most promising ones – dermocosmetics and wound care. The analysis covered respective use cases on different markets and geographic areas, potential new use cases associated with various skin diseases, model of cooperation with established market players as well as potential regulatory pathway to market authorization with comparative analysis with our closes competitors,
b) An extensive market analysis was also purchased from a specialized entity
c) A detailed financial plan and financial model to simulate Enzybiotx’ future profitability and return from investment,
d) Freedom to Operate analysis ordered,
e) Secured the IP protection for both enzymes,
f) Product validation – tests comparing the enzyme characteristics with the enzyme of our direct competitor, especially the effectiveness of AuresinePLUS. Results of various tests were compared to that of our competition and AuresinePLUS turned to be at least as effective with one large advantage over their enzyme – AuresinePLUS is effective in a much wider range of temperatures,
g) Mentoring and coaching – aimed at helping the female founder with expanding our network, learning how to approach large corporate players, fine-tune pitching, gain visibility on the market and attracting further funding,
h) Expansion of the official webpage – new sections were added.
